<p>Association of atorvastatin with the risk of hepatotoxicity: a pilot prescription sequence symmetry analysis</p>

Haiping Zhang, Jiani Wu, Zhuolin Zhang, Haisheng Qian, Yifan Wang, Miaomiao Yang, Yinchu Cheng, Shaowen Tang

Therapeutics and Clinical Risk Management · 2019 · 11 citations · 30 references

DOIFull text

Open access

Concepts

Abstract

Purpose: This study aimed to evaluate Atorvastatin (ATO)-associated hepatotoxicity using prescription sequence symmetry analysis (PSSA), based on a health insurance database of a Chinese population living in Jiangsu Province, China. Methods: Patients prescribed ATO and hepatoprotective drugs in 2017 were identified, and the run-in period was determined based on the “waiting-time” distribution. Adjusted sequence ratio (ASR) and 95% confidence interval (95% CI) were calculated to estimate the risk of ATO-associated hepatotoxicity under different time intervals or based on gender and age stratification. Results: A total of 2,549 patients, with 1,518 filling the ATO prescription first and 1,031 filling the ATO prescription second, were analyzed. After setting the run-in period as 30 days and the time interval as 15, 30, 60, 90, 120, and 180 days, the ASRs were 1.492 (95% CI: 1.367–1.652), 1.399 (95% CI: 1.308–1.508), 1.280 (95% CI: 1.213–1.357), 1.292 (95% CI: 1.234–1.356), 1.278 (95% CI: 1.226–1.336), and 1.274 (95% CI: 1.229–1.323), respectively. No significant difference was observed between different genders and ages (χ 2, =0.161, P =0.688; χ 2, =1.565, P =0.211, respectively). Conclusion: This is the first study conducted in a real-world setting to evaluate the relationship between ATO and hepatotoxicity using the PSSA in a Chinese population. We found a 1.3- to 1.5-fold increase in risk of hepatotoxicity following ATO, with the greater risk occurring within the first 30 days of treatment. Keywords: atorvastatin, hepatoprotective drug, prescription sequence symmetry analysis, health insurance database

References

30